Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IDEAYA Biosciences ( (IDYA) ) has provided an update.
On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.
The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
The overall stock score reflects significant financial challenges, with declining revenues and consistent net losses being the most impactful factors. While technical analysis shows positive trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences is a biotechnology company focused on the discovery and development of precision medicine and immuno-oncology therapies. The company specializes in developing small molecule inhibitors for genetically defined cancers and has a particular focus on uveal melanoma, a rare and aggressive form of ocular cancer.
Average Trading Volume: 1,227,681
Technical Sentiment Signal: Buy
Current Market Cap: $2.56B
For detailed information about IDYA stock, go to TipRanks’ Stock Analysis page.